Microparticles, Microspheres, and Microcapsules for Advanced Drug Delivery

Abstract

Multiparticulate drug delivery systems offer outstanding advantages to experts and patients, such as: - choice of dosage form for the desired drug delivery route (peroral tablets, parenteral injections); - modified and targeted (even site-specific) drug release and delivery; - more expectable pharmacokinetics with reduced intra- or inter-subject variability; - more homogenous di stribution in the physiological environment; - stable fixed-dose combina tio ns of drugs; - dose titration and less dose-dumping; - patient cen-ricity through better compliance (e.g., patients with dysphagia) and adherence; - individual therapy (e.g;., for pedia tr ic or geriatric population); - improving; stabiiity of the medicinal preparations; - isolating the constituents to ensurebetter compatibility; - innovative products with a prolonged life? cycle through pa tent protection. Besides the emulsification, depending on the excipient thermal annealing and chemical cross-linking take part in the immobilization of the active ingredient. 3.Types and Mechanism of Drug Release The process of drug release of microparticulates, produced by special manufacturing technologies and/or possibly containing special excipient(s), is the result of various phenomena and mechanisms (dissolution/diffusion, osmotically driven release, erosion) (Figure 3). The combination of polymers of different properties is a common technique to improve the particle characteristics and performance. Because of their opposite charges, alginate and chitosan at low pH form a polyelectrolyte complex [76], thus decreasing the porosity of the polymer network and delay the release of the API (Table 6). Spray Drying Spray drying is widely used in the industry for microencapsulation of volatiles, probiotics, and viable cells. Besides the obvious drawback (high loss, low yield), the numerous advantages make this technology very popular (uniform particle size, all steps carried out in one apparatus, use of organic solvents, the capability of encapsulating heat-labile materials).

Headnote

Received: 11 July 2019; Accepted: 1 August 2019; Published: 9 August 2019

Abstract: Microparticles, microspheres, and microcapsules are widely used constituents of multiparticulate drug delivery systems, offering both therapeutic and technological advantages. Microparticles are generally in the 1-1000 pm size range, serve as multiunit drug delivery systems with well-defined physiological and pharmacokinetic benefits in order to improve the effectiveness, tolerability, and patient compliance. This paper reviews their evolution, significance, and formulation factors (excipients and procedures), as well as their most important practical applications (inhaled insulin, liposomal preparations). The article presents the most important structures of microparticles (microspheres, microcapsules, coated pellets, etc.), interpreted with microscopic images too. The most significant production processes (spray drying, extrusion, coacervation, freeze-drying, microfluidics), the drug release mechanisms, and the commonly used excipients, the characterization, and the novel drug delivery systems (microbubbles, microsponges), as well as the preparations used in therapy are discussed in detail.

Keywords: multiparticulate formulations; polymer excipients; processes for microparticles in therapy; structure and drug release; microfluidics; microbubbles; microsponge

1.Introduction

Microparticles, microspheres, and microcapsules are common constituents of multiparticulate drug delivery systems offering numerous advantages based on their structural and functional abilities [1], and their application is suitable for convenient and tolerable drug administration via several routes.

Depending on the formulation, they can be incorporated into different pharmaceutical dosage forms such as solids (capsules, tablets, sachets), semisolids (gels, creams, pastes), or liquids (solutions, suspensions, and even parenterals).

An advantage of microcarriers over nanoparticles is that they do not traverse into the interstitium over the size of 100 nm transported by the lymph, and thus act locally [2]. Possibly toxic substances can be carried encapsulated and liquids can be handled as solids in the form of dried microparticles.

In the case of multiparticulates, the dose is distributed in many small separate particles, which carry and liberate a part of the dose, hence the malfunction of an individual subunit does not cause the failure of the whole dosage.

Multiparticulate drug delivery systems offer outstanding advantages to experts and patients, such as:

- choice of dosage form for the desired drug delivery route (peroral tablets, parenteral injections);

- modified and targeted (even site-specific) drug release and delivery;

- more expectable pharmacokinetics with reduced intra- or inter-subject variability;

- more homogenous di stribution in the physiological environment;

- stable fixed-dose combina tio ns of drugs;

- dose titration and less dose-dumping;

- patient cen-ricity through better compliance (e.g., patients with dysphagia) and adherence;

- individual therapy (e.g;., for pedia tr ic or geriatric population);

- improving; stabiiity of the medicinal preparations;

- isolating the constituents to ensurebetter compatibility;

- innovative products with a prolonged life? cycle through pa tent protection.

From the viewpoint ef technology, microencapsulation provides several advantages: microparticles are formulated in ordee to protect the core from the envhonment; masking an unpleasant taste; preserving volatiles or the viability of the cells; separating incompatible substances; protecting the body from the side ef-erts; and optimizing, prolonging, or targeting thn effect of a drug.

The polymer excipient protects; the active pharmaceutical mgredient rAPI) from the environment (oxidation, temperature, pH) or the body from the irritative, or mucosa-damaging effect of the drug substance. The lesion (e. g., bisectioning) of the multiparticulate sofid dosage form (i.e., micropellets in spansule or compeessed) affects only r smafi number o f units, thus does no. resuh in a si gnificant change °C the blood level.

However, there ere sonae limitations, such as higher product costs due to the more expensive excipients in the formulations or to the mere sopiaisticated equipment and procesees, ar well as stricter quality control. In add ition, some constituents may not meet the requirements for b iocompatibility and biodegrodation.

2.Construction and Structure

Microparticles' sizes range from 1 to 1000 pm and the well-known matrix or reservoir structure they exist in have various differenr structuues (Figure 1). Boyond fiae excipients used, the structure and the shape determines the function as weli. Multiparticulate drug; delivery systems (micropellets, microgranules, microspheres, microcapsules, microsponges, liposomal preparations) attract attention because of then wide range of favorable teehnological proper ties.

Microparticles may be characterized as either a homogenous or heterogenous structure depending on tise formulation rnd procossing. Usually the spheroid shape ie preferred sines it makes tise further processing (p.g., coating) easier.

2.1.Microspheres and Microcapsules

Microspheres can be characterized as matrix systems in which the drug is homogeneously dispersed, either dissolved or homogenously susp ended [3]. Microcapsules are heterogenous particles where a membeane shell is surround ing the crrr form inge a reservoir (Figure 2) [4].

A classical microsphere structure contains solid or liquid (API dispersed or dissolved in r matrix. Microcapsules are reservoirs of microscopic size surrounOed by a wall that: is able So control tOr rele ase from She reservoir.

The size plays a role in the gastrointestinal performance: microparticles under 800 pm get through the pylorue without the influencr of gastric emptying, thus eliminuting the interpersonal and intrapersonal (nutritien-based) differences.

Particles larger than 100 nm stay at the site of administration until the phagosomal clearance. Lymphatic] uptake and node accumulation i s most significant between 10-80 nm [2]. The foreign body response is (decreased by thr application of spheres with a dirmeter of 1.5-2.5 mm compared to that of smaller diamtter spheres [5].

The surfate charge hear a kry role in the aggreration oi the particles. Aggregation hinders optimal admimstration and drug delivery (e.g., compromises content uniformity of doses, occludes normal blood flow).

Porosity also has a significance in she in vivo performance in cell transplantation. Porous materials facilitate vascularization relativo to non-porous biomatermls. Ai porosity of1 30-40 pm leads to the polarization ot macrophages, causing elevaied tissue repair [5].

Several unique mtsotropic colloidal microstructures have lately been created with special properties.

2.1.1. Janus Particles

These microparticles with a certain shape and phase anisotropy, created by alloying the distinct properties (hydrophilic, hydrophobic) of the separated excipients, are used as multifunctional imaging probes and sensors [6,7]. The anisotropic response to external signals has also been exploited in the preparation of color-changing traffic signals.

2.1.2. Patchy Particles

Spherical geometries with concave, convex, or flat patches on the polystyrene sphere's surface have also been created via colloidal fusion and concomitant shrinking (Figure 1). The patchy particles can form clusters, and by patch-to-patch bonding between oil patches, can build supracolloidal architectures (tetrahedral, hexagonal) that can withstand drying forces and show the ability to reversibly expand several times their original volume in a swelling agent [8]. Microfluidic techniques give rise to the creation of anisotropic geometries.

Magnetic nanoparticles embedded into nonplanar, bullet-shaped microneedles give access to mild invasive therapy [9].

2.2. Liposomes

Liposomes are lipid vesicles with one or more phospholipid bilayers and their structure comprises small unilamellar vesicles (SUV: 20-100 nm), large unilamellar vesicles (LUV: >100 nm), multilamellar vesicles (MLV: >500 nm), oligolamellar (OLV: 0.1-1 pm), giant unilamellar liposomes (GUV: > 1 pm), and multivesicular vesicles (MVV: > 1 pm).

For ophthalmic delivery, they represent ideal drug delivery systems for both hydrophilic and hydrophobic APIs by performing a cell-membrane like structure. The negative or positive charge can contribute to the bioavailability: cationic liposomes (e.g., fabricated with didodecyldiethylammonium chloride, stearylamine) exhibited better efficacy at the surface of cornea with a negative charge. Liposomes can interact with the cells via several mechanisms: interaction with the cell surface components, fusion with the membrane, endocytosis via phagocytic cells, or swap by bilayer components. The methods of preparation are also versatile: solvent evaporation, double emulsion-evaporation, or reverse-phase evaporation [10].

2.3. Colloidosomes

Colloidosomes are microcapsules that contain a hollow or hydrogel core and their wall is composed of self-assembled colloidal particles. Their sizes range from 10-20 nm to micrometers. It was found that colloidosomes have selective permeability where drugs can diffuse through their shells via size exclusion [11]. They can be stabilized by solid excipients (e.g., Fe2O3, CaCO3, colloidal anhydrous silica) forming a Pickering emulsion [12]. Besides the emulsification, depending on the excipient thermal annealing and chemical cross-linking take part in the immobilization of the active ingredient.

3.Types and Mechanism of Drug Release

The process of drug release of microparticulates, produced by special manufacturing technologies and/or possibly containing special excipient(s), is the result of various phenomena and mechanisms (dissolution/diffusion, osmotically driven release, erosion) (Figure 3). Generally, these mechanisms take place side by side and one or the other mechanism provides a greater role during drug release [13]. In the microparticulate, when the active pharmaceutical ingredient is embedded in a polymer matrix (Figure 3), the behavior of the polymer system is crucial during dissolution, but depends on many factors (drug properties, formulation, release medium, etc.) [14].

In the case of a polymer matrix, the diffusion of the active ingredient can be through the intact polymer network or through the pores filled with water. Water-soluble drugs may also dissolve in the aqueous pore networks. Water uptake causes polymer chains to swell, indicating the formation of new pores and/or osmotic pressure. During swelling, the volume increases, the effective diffusion coefficient of the drug is increased, and more pharmacon molecules enter the aqueous part. Erosion of the polymer matrix (bulk/surface) is also possible.

In the case of polymer coated microparticles, the film-forming polymer may dissolve in the medium or act as a water-insoluble, permeable or semipermeable membrane. In the former case, the diffusion is predominantly due to the release of the active ingredient. In the case of a semipermeable coating, the osmotic phenomenon should be taken into account. It is also possible to use water-soluble pore formers, which, by creating pores, accelerate the dissolution profile [15,16].

In the case of smart drug delivery microparticle systems, the release of the drug; occurs 'via a stimulus. It is possible that ont, two, or more (multiple) stimuli are required for dissolution (Figure 4). The stimulus for (trug release may loe internal or external and be classified es physical, chemical, or even microbiological. Opening and closing signals of these systems are also possible, creating feedback [17].

Magnetic Microcapsules

Magnetic microspheres are supramolecular particles that circulaţie through capillaries without causing occlusion in the form of emboly (<4 pm) but show a ferromagnetic character such that they can be dragged into the harget tissue with a magnetic fisld oS 0.5-0.8 T [18]. Magnetic microparticles for medical applications have been developed, such as magnetic resonance imaging (MRI) and drug delivery, and they are a promising choice in tumor therapy accompanied by hyperthermia. The release can be fine-tuned by the strength of the applied magnetic heating: with a gentle magnetic effect, the particles react with shrinkage and slow drug release, and with intense heating, the structure disruption induces the shrinking, which leads to a burst release [19].

Their great advantage lies in the effective method of targeting the drug molecule to the desired site to be treated (i.e., the tumor) with higher therapeutic efficacy and lower toxicity. The reduction of dosing frequency enhances the patient's compliance.

The production involves emulsion methods (multiple and phase separation polymerization, solvent extraction, hot melt microencapsulation, dispersion copolymerization).

4.Formulation and Manufacturing

4.1.Composition and Excipients

The use of plant, animal, or microbial-origin biopolymers are propitious; semi-synthetic cellulose derivatives and biodegradable or non-biodegradable synthetic polymers are used as well. The formulation is usually based on polysaccharides or proteins, but waxes and lipids also play a role in the construction. Nonpolymer excipients play a role in crosslinking the polymer chains (CaCl2, glutaraldehyde, poly-L-lysine, etc.), thus forming and hardening the polymer network of the drug delivery systems. The most commonly used polymers and their important microencapsulation-related properties are summarized in Tables 1-5.

The combination of polymers of different properties is a common technique to improve the particle characteristics and performance. Because of their opposite charges, alginate and chitosan at low pH form a polyelectrolyte complex [76], thus decreasing the porosity of the polymer network and delay the release of the API (Table 6).

Funami et al. [97] proved that galactomannans, including guar gum, tara gum, LBG, or konjac gum (glucomannan), influence both the short- and long-term retrogradation process of starch by controlling the gelation, hindering the crystallization, and improving the water-holding capacity of starch.

Farris et al. [88] developed a peroral gene delivery system, where DNA was encapsulated in chitosan nanoparticles and the particles were protected from the gastric environment by embedding the nanoparticles into zein matrix microparticles with a W/O emulsification method. Zein forms a relatively brittle film; however, alginate was successfully administered to decrease the rigidity of the wall [87].

Several studies show that copolymerization between synthetic and natural polymers helps to increase biocompatibility and cell viability (agarose-Carbopol®, hyaluronic acid-polyethyleneglycol) [98]. Hydrophobic excipients (poly-?-caprolactone) can modify the release of low-solubility drugs from alginate by forming hydrophobic interactions with the drug molecule, thus prolonged release can be reached [94].

Controlled-release, porous, floating microparticles were formulated by combining polypropylene-Eudragit® RS, ethylcellulose polymers [95].

Mahou et al. successfully studied the addition of vinyl-sulfone terminated polyethyleneglycol to alginate and thus eliminated the use of polycations for human foreskin fibroblast cell encapsulation from a cell culture medium [93].

Wells et al. reached prolonged drug release and light-sensitive drug delivery with the chemical modification of PEG and chemical crosslinking with alginate.

Dalpiaz et al. studied the nasal absorption of zidovudine by deoxycholic-acid-conjugated chitosan microparticles and found that the particles could get through the blood-brain barrier, in contrast with active efflux transporters in rats [99].

Alginate microcapsules show shrinking and lower stability in an acidic medium. κ-carrageenan locust bean gum gel beads show lower sensitivity to acidic conditions than alginate beads. A limitation of their use is that the formation of κ-carrageenan locust bean gum beads requires a higher amount of potassium or calcium ions, which in terms of a healthy diet, are not acceptable in high amounts. In cell transplantation, alginate is applied because of its excellent biocompatibility and biodegradability. Alginate, however, has some limitations: uneven porosity, poor mechanical strength, weak wall-formation, and easy rupture on reaction to osmotic change have been reported. To overcome these drawbacks, excipients such as the polyelectrolytes polystyrene sulfonate (PSS) and polyallylamine (PAA) were examined in cell microencapsulation, which improved the physical structure of polyelectrolyte gels and complexes by reducing pore size in the microcapsule membrane. Osmotic or mechanical stress caused lower cell leakage of these microcapsules [91]. The incorporation of PSS and PAA were shown to attract inflammatory cells and to trigger an immune response. The same study showed that ursodeoxycholic acid increased mechanical stability and did not affect cell viability.

Poly-L-ornithine in combination with alginate has been shown to prevent post-transplant inflammatory response and has protected the microcapsules in vivo over the first week after grafting [90].

As artificial cell therapy, an alginate structure strengthened by poly-L-lysine was used for encapsulation [100]. The alkylamino groups of the polyamide chain bonds via electrostatic interactions with alginate, thus the matrix structure has reduced porosity and good immunoprotection.

4.2.Processes for the Particle Formation

From the point of view of the industrial performance, the most important methods for microencapsulation are the air suspension method, spray-drying, and coacervation. Figure 5 summarizes the most important techniques.

4.2.1. Coacervation

Coacervation related to the formation of calcium alginate can be considered a classical method for the preparation of microspheres and microcapsules. Calcium-ions form crosslinks between the a-L-guluronic acid a nd ß -D-mannuronic acid units of alginate, thus org anizing the polymer chai ns into an "eggbox-struature." This chemical bonding gives trie possibility of forming stable microspheres or core-ahell structured microcapsules (F igures 6 and 7).

Coacervation is defined as the separation of liquid phases in colloidal solutions [101]. During coacervation, the active ingredient cart be dtspersed in the coating polymer solution and at a specifio environmental influence i-onic, jot-, thermal change), phase ¡separation occuts, while the core materiel is encapsulated by the wall-forming polymer. Simple coacexvetion is based on incompetibilities beXween the polymers. In most coses, it is caused by salting-out (di- or trivalent cation, as it happens with alginate and Ca2+ or Ba2+, pectin and Ca2+). The particle size mainly depends on the excipignts' properties (viscnsity, sueface tension) and stirrer setup [102,103].

During complex coacece ation, polyele ctrolyte polymers with opposite charges form an insoluble complex and meanwhile encapsulate the active ingredient. pH is important in complex concervation, as the iso electric point of the polymers hax to be taken into consideration.

Hydrophobic components are often encapoulated with coacervation. In the case of hydrophilic componrnts, a double emulsion procett followed by a coacervation proves to be successful way to form a core-shell structure microcapsule [79]. As r result of coacxrvatign, the product contains a high amount o) solvent, which needs te be evaporated from the product.

For drying, besidee the eommon prxcesset, lyophilization (fceeze-drying) offers a choice. This is an expensive method, leut effective for heat-sennitive actives. Shrinking of the particles can be partlg avoided; the end produci; however, hat a htgh porosity, which is an advantage in fasn release prenarations to promote the water uptake, but is an obvious drawback in the formuta)ion oO sustained-release preparations.

4.2.2. Air Suspension Method/Fluid-Bed Coating

(Wurster (1959)) [104] has successfully administered fluidization in macroencapsulation for the coating of solid particles, but it was also administered to encapsulate small particles in the size range of 74-250 gm by Hinkes et al. [105]. The great advantage is that during the process, the particles are suspended in an air (or inert gas) stream, in constant mixing, relative independently from each other and the wall material solution or dispersion is sprayed on their surface, then dried inside the coating chamber. The particle size can be tuned by the well-controllable process parameters: properties of the core (density, hygroscopicity, surface area, particle size and shape, melting point, wettability, solubility, volatility, compressibility, crystallinity, hardness, cohesiveness, adsorption, friability and flowability of the core material). Concentration and quantity of wall material, inlet, outlet air temperature, and spray settings are also critical for the process.

4.2.3. Extrusion through a Nozzle

Extrusion through a nozzle is a common method in the formation of gel particles. Many factors influence the formation of microgels: the concentration, feeding rate, and surface tension of the polymer solution, solvent, temperature, and nozzle diameter [3,106,107]. The solidification of the formed microgel particles is performed in an additional step. For solidification of the gel, coacervation (either simple or complex) is an optimal choice. The formed particles are collected in a solidification liquid (ionic or polymer solution). The size and shape control of particles is dependent on various factors. The distance, concentration, surface tension of the solidification liquid, and the time of the process have a significance in the particle size and the physical properties of the beads (gel strength, porosity, etc.). The most important limitations of the extrusion are the viscosity of the polymer because of potential blockage of the nozzle; as such, the settings for optimal, narrow particle size distribution, and shape are required. For the scale-up of the process, multiple-nozzle solutions have been presented.

4.2.4. Vibrational Jet/Electrostatic Extrusion

The particle formation via extrusion is completed by various processes: vibrational jet technique means that a changing frequency vibration separates the laminar jet into beads). At the electrostatic extrusion [108] the jet is subjected to an electric field, where having reached a certain voltage (5-6 kV), particles are created, the repulsive forces additionally hinder their aggregation. The applied elevated electric potential does not cause cell death [109].

4.2.5. Spinning Disk and Cutting Wire

These devices mechanically aid the particle formation and disaggregation [110].

4.2.6. Spray Drying

Spray drying is widely used in the industry for microencapsulation of volatiles, probiotics, and viable cells. Besides the obvious drawback (high loss, low yield), the numerous advantages make this technology very popular (uniform particle size, all steps carried out in one apparatus, use of organic solvents, the capability of encapsulating heat-labile materials). The emulsion is sprayed into a chamber, where warm air dries the particles, and as a result, regular shaped, micron-sized, uniform particles are created.

The extruded wax particles can be solidified using congealing, which offers a solution for embedding hydrophilic component to perform sustained release via the slow erosion of the wall in the biological medium.

4.2.7. Supercritical Fluid Precipitation

This technique is capable of constructing very uniform particles, but its use is more significant in nanoencapsulation [111].

4.2.8.Freeze-Drying

Freeze-drying is successfully used in the microencapsulation of protein APIs. The process consists of freezing, sublimation, primary drying, and secondary drying. At the freezing step, the eutectic point of the components is taken into consideration. Lyoprotectants or cryoprotectants (trehalose, dextran) can stabilize API molecules during the process by replacing water, forming a glassy matrix, reducing molecular mobility by establishing hydrogen or van der Waals bonds between the molecules [112]. Despite its high cost, it is an advantageous process for heat-sensitive molecules.

Freeze-drying provides solidification, which then allows particles to be reconstituted in an aqueous medium (Figure 8).

Table 7 summarizes the most important methods along with the parameters of the initial and final form of mic roparticles.

4.2.9.Microfluidics in Microparticle Fabrication

Microfluidics also presents promising results regarding microparticle production [113]. A wide range of microfluidic plates have been created concerning their various structure, material, and size [114]. Various methods are used for the engineering of microparticles such as continuous flow-based and electrowetting-based droplet generators.

Microfluidic Droplet Generators (MFDG)

Microflaidic droplet generaters (MFDG) with a f-]unctian, co-flowing junction, and flow-focusing geometriee are able to create, depending on the settings, monodisperse epherical or spheroid droplets [114] . The microfluidic-based droplet generation can be implemented using active or passivd methods. In the passive method, dooplets can be produced in sqneezing, dripping, jetting, tip-streaming, and tip-multibreaking modes, depending on thc competition between capillary, viscoas, end inerţiei forces [115]. In active control, droplet generation ceo be mrnipairted by either applying rdditionri forces from electricei, megnetic, end centrifugei controls, or modifying intrinsic forces vie tuning fluid velocity and materiel properties including aiscos, ty, irterfac ial tension, chennel wetfability, and fluid density [1S5].

Coexieiiy essembied devices;, in combinetion with emalsificrtion methods, led to the production of monodisperse microcepsules or Jenas perticies [116]. The poiymerizetion occars asing e concomitent chemical or physical reection besed on the natare of the polymer [117]. Figare 9 presents particie formation teronge я PDMS (polydimethyisiloxane ) hydrodynamio focusing apparatu s of a W/O/W e^inete system in oii as a carrier liquid. The algine te droplets were solidified via coacerve tion (own experiments) .

Wu et al. [96] demonstrated that irt the case of monodisperse rifampicin-PLGA core-shell microcapsules, the burst-re]ease can be decreased with increased encapsulation efficiency, and the release can be controlled by increasing the wall thickness.

4.2.10. Lithography

Contact lithography was originally developed for the semiconductor industry. It is, however, successfully applied in the replication of nonspherical particles of 500-1000 pm in size. The pattern is transferred from a photomask to a photopolymerizable material (e.g., polyethylene-glycol- diacrylate) using light [118]. Continuous flow lithography has better particle resolution and improved throughput. The monomer solution is pumped through a microfluidic device, where photopolymerization occurs. The polymer particles (sometimes of extreme shape) are collected after having left the device [9,119] and have been used for the controlled synthesis of bullet-shaped, 12.4-pm long, magnetic and non-magnetic microparticles using stop-flow lithography, which gives the possibility of executing mild invasive drug delivery via microneedles.

5.Characterization

5.1. Morphology

Size plays a crucial role in the in vivo performance of microparticles. Particles larger than 100 nm stay at the site of administration until the phagosomal clearance. Lymphatic uptake and node accumulation is most significant between 10-80 nm [2].

5.1.1. Particle Size Analysis

Particle size analysis of microparticles above the diameter of 3 pm is in most cases carried out based on laser light diffraction (LD) method or using a Coulter counter. In LD, the distribution indicates the span-value, and d0.i, d0.5, and d0.9 are the parameters that can be used to compare the results. Span-value indicates the size distribution and is calculated based on the following equation:

... (1)

where 90% of the particles are under the diameter d0.9,10% of the particles are under the diameter d0.1, and 50% are under the diameter d0.5.

The polydispersity index (PDI) determined by dynamic laser light scattering indicates the size distribution in the lower size region of microparticles.

5.1.2. AFM (Atomic Force Microscopy)

AFM is a technique providing information about the surface of microparticles in nanoscale by profiling the surface [120].

5.1.3. Coulter Counter

A Coulter counter gives an absolute particle number per volume unit for various size ranges and is very important in the particle analysis of microparticles for intravenous use [121].

5.1.4. Image Analysis

The shape determination can be more accurately achieved using microscopic (light or scanning electron microscopy) image analysis. The shape is characterized by the roundness, aspect ratio (AR), and the Feret-diameter. Roundness (R) is calculated using ... , where P is the perimeter, and A is the projection area. The aspect ratio is calculated using ... where Do is the longest orthogonal diameter perpendicular to Dmax.

The aerodynamic size distribution (indicator of the particle deposition during inhalation) can be investigated using cascade impactors (powders, aerosols, and sprays). The deposition is not solely based on the particle size, the flow depends on the particle shape and density as well [120].

5.2. Physicochemical Properties

Zeta-Potential Analysis

The surface charge of the particles influences physical properties (e.g., tendency to aggregation); it also has a tremendous role in their biological performance: negatively charged surfaces (polysaccharide-based natural molecules, e.g., polyalginic acid, hyaluronic acid, polymethacrylic acid, etc.) attract to tissues in inflammations and are hemocompatible. Positively charged microparticles (chitosan, Poly-L-lysine), however, present a mucoadhesive character and are non-hemocompatible [122]. Zeta potential and particle size can be determined using photon correlation spectroscopy. The dynamic light scattering measurement is based on the Brownian movement of the particles. Zeta potential measurements present valuable data concerning the aggregation potential of surface charged microparticles in a suspension (above ±30 mV stable suspended particles because of repulsion), and in indicating whether the surface-charged molecule is encapsulated or adsorbed on the surface [123].

5.3. Physical Properties

5.3.1. Density

The density of particles determines the floating capacity and concomitant disintegration or swelling of the particle. The pycnometric method with helium gas can be used to determine this value [124].

5.3.2. Porosity

The porosity of microparticles has a significant role in the water uptake, swelling, reconstitution, and release mechanisms. This parameter can be measured directly using mercury porosimeters [125].

5.3.3. Microcomputed Tomography

The indirect assessment of porosity can be deducted from a microcomputed tomography assay based on the 3D internal trabecular separation for calcium-alginate microparticles [126].

5.3.4. Flowability and Compressibility Studies

The flowability, Carr's index, Hausner ratio, and angle of repose are significant for particles applied in the dry state. These tests can be executed as it is described in the official pharmacopoeias (e.g., European Pharmacopoeia, Unites States Pharmacopoeia).

5.3.5. Mechanical Test

The tensile strength and the elasticity of microparticles can be tested with a texture analyzer, where the compression force is detected relative to the distance, and the maximum compression force and hardness can be calculated, which indicate the mechanical resistance of the shell or the matrix structure [124].

5.3.6. Swelling

An equilibrium swelling study can be performed to observe the behavior of dry particles under various conditions (Figure 10). The swelling index (S%) can be calculated using the swollen particle diameter (ds) and the initial particle diameter prior to reconstitution (di), as follows:

... (2)

5.3.7.Wetting Property

The wetting property of the excipients can be determined using contact angle measurements [127,128].

5.4 . Drug Entrepment Efficiency

The success of drug loading can be expressed by the actual loading and the entrapment (encapsulation) efficiency:

The actual drug; loading is:

... (3)

The general formula for calculating the entrapment efficiency value is:

... (4)

The ideal entrapment efficiency (100%) is influenced by various factors such as the type and circumstances of the process [129].

5.5. Drug Release

5.5.1.In Vitro Dissolution Test for Multiparticulates

USP 42-NF 37 suggests different methods for the dissolution of multiparticulate preparations. The apparatus and the volume are chosen based on the dosage form performance in the medium and the volume. Compendial rotating basket (USP Apparatus 1), a reciprocating cylinder (USP Apparatus 3) can be used for nondisintegrating coated beads, or a flow-through cell (USP Apparatus 4) can be used for multiple dosage forms (beaded products), where sink conditions are provided.

Polymers of ionic character perform differently under various pH conditions. The independence or dependence of drug release on the ionic strength of the medium can be proved using distinctive pharmacopoeial methods. The medium ranges between the physiological pH 1.2-7.5 hydrochloric acid or phosphate or acetate buffer with or without enzymes, depending on the route of administration or the behavior of the polymer in the medium (e.g., swelling, ionization (IEP)). The use of surfactants is possible, usually over its CMC value.

As a noncompendial apparatus, a mini-paddle-equipped small-volume apparatus, dialysis tubes, or rotating bottle can be used.

The in vitro release mechanisms (diffusion, erosion, osmotic release, or a combination of the previous) can be interpreted based on the models of Fick, Higuchi, Korsmeyer-Peppas, Weibull, and Kopcha [130,131].

5.5.2. Dissolution Test for Inhaled Particles

Inhaled particles deposit in the tracheobronchial tract depending on the size, density, and shape of the particles. The mucus layer that provides the absorption site for drugs has a small volume and the renewal of the absorption layer is different from that of the gastrointestinal tract; therefore, the development of dissolution methods different from the traditional is used. USP 2, the rotating paddle apparatus, can be used with certain modifications. The drug is set into a special cassette and an apparatus capable of a 150 mL dissolution medium is used, agitated using mini paddles [132].

The dialysis bag method is also useable. The drug is set in the semipermeable dialysis bag, which is immersed in the dissolution medium. The drug diffusion occurs between the two liquid phases, and although both static and sink-conditions are maintained, the method does not simulate the air-liquid transition.

5.5.3. In Vitro Performance of Intramuscular Injections

The in vitro dissolution study of the long-acting intramuscular injection, Risperdal® Consta®, where the small interstitial volume provides an alternative dissolution method, was carried out in a flow-through cell apparatus equipped with glass beads of 1 mm diameter and a pump [133]. The in vitro dissolution data of the accelerated test, performed at a temperature above the glass transition temperature of the polymer, correlated well with the previously published in vivo data.

In both the modified Franz diffusion cell [134] and Transwell® [135] systems, drug powder is poured on a semipermeable membrane, which is located above the acceptor medium and diffuses through the membrane during the test. Small volume, agitation, and regularly withdrawn samples (sink conditions) provide the in vitro simulation of the in vivo performance.

DissolveIt® apparatus [136] presents in vitro dissolution and absorption by mimicking the in vivo performance with a membrane separating the simulated air-blood barrier in the tracheobronchial region of the lung and a flowing blood simulant.

5.5.4. In Vitro Dissolution Test for Topical Microsponge Preparations

A Franz diffusion cell with silastic membranes and a sink condition providing solvents as an acceptor medium has been applied to test benzoyl-peroxid-containing microsponge gel preparations [64].

6. Other Studies

6.1. Spectrometry

Fourier-transform infrared (FT-IR) and powder X-ray diffractometry (PXRD) analysis can be performed to follow the intramolecular changes during microencapsulation [81]. Nuclear magnetic resonance (NMR) studies underline the conformational changes in polymers during complexation [137].

6.2. Thermoanalytical Methods

Thermogravimetry (TG) and differential scanning calorimetry (DSC) give valuable data of the thermal behavior of the polymer. The measurable glass transition temperature plays a significant role in the production and the release mechanisms as well.

In the case of mucoadhesive systems, the tensile strength test, shear strength test, and the peel-off test or in vitro wash-off test can be performed [61].

6.3. Biocompatibility

A tetrazolium-based colorimetric assay, such as an MTT (methylthiazolyldiphenyl-tetrazolium bromide) assay, proved good to screen the cytotoxicity of hydrophylic polymers [138].

7. Applications in the Therapeutical Practice

Several types of multiparticulate sytems and product examples are detailed in Table 8 according their type, dosage form with route of administration, drug and key excipient, and indication for use.

Solid multiparticulates usually involve coated pellets or microtablets in order to ensure gastric resistance (e.g., for acid labile proton pump inhibitor compounds) or to prolong the duration of action and optimize the pharmacokinetic profile. Smart carrier systems react to changing pH, electric impulse, magnetic field, and/or temperature, and have been developed in many platforms (pellets, microgranules, microspheres).

Patient-centric medication involves the development of patient-friendly devices (e.g., DPI-Dry Powder Inhaler) and administration routes. Inhalatives, ODTs, and nasal administration could be an opportunity to reach a systemic effect. There is broad research on this field, however, there is only a limited number of preparations approved by the authorities

Sustained-release injectable depot systems are capable of forming a reservoir at the site of administration and release the API over a longer period. This property is advantageous in the treatment of psychotic patients, or in the medication of children with acute diseases.

7.1. Insulin for Inhalation (Technosphere®)

AfrezzaTM is an immediate-release insulin formulation for Type 1 and Type 2 diabetes patients with an optimal bioavailability (25%). The pulmonary applied preparation consists of microparticles (2-3 pm) of self-assembled fumaryl diketopiperazine (FDKP) (Mw = 452.46 Da) molecules. In this preparation, FDKP nanocrystals are formed via a pH-induced crystallization process, and the nanocrystals are self-assembled into a spherical microparticle, like a deck of playing cards. The front and back sides of the "cards" provide the spheres with a high surface area, and the distance between the layers provide the extremely high porosity, low density, and convenient aerodynamic character to deposit into the distant alveolar regions where the API dissolves rapidly at the alveolar surfactant pH. Depending on the API molecular weight, local (>100,000 Da) or systemic absorption is possible. Special inhalers (Dreamboat® or Cricket®) are designed for optimal application [139].

7.2. Depocyte® (Parenteral Suspension)

Depocyte®, a liposomal product, is a pyrogen-free, parenteral suspension containing cytarabine developed for the treatment of neoplastic meningitis (NM) via controlled release. Depocyte® is a slow-release formulation created using DepoFoam™ technology, which includes microscopic spherical particles (3-30 pm) and is suitable for encapsulating hydrophilic compounds in a "honeycomb-like structure" of separated water-containing chambers. Lipid membranes separate each adjacent chamber. Drug release is carried out over an extended time via erosion and/or reorganization of the particles' lipid membranes. The honeycomb architecture of multivesicular DepoFoam™ particles gives allows for a comparatively high drug loading. The injection comprising 96% aqueous foam and 4% biodegradable lipid [140] has to be administered intrathecally every two weeks and it is metabolized by the usual metabolic pathways for triglycerides, phospholipids, and cholesterol.

7.3. DepoDur™

Epidural morphine sulfate sustained-release liposome injection DepoDur™ is a single-dose preparation administered at the lumbar level by the epidural route before operations. The lipid foam contains multivesicular lipid-based particles with aqueous chambers that encapsulate the active drug. The foam releases morphine during a 48-h period via erosion, namely the rupture of the microvesicles (of 17-23 pm in median diameter).

7.4. Microsponge Delivery System (MDS)

Topical delivery of drugs can be achieved with microparticles of very high porosity. These structures (of particle size of 5-300 pm) can entrap and release drugs with a controlled rate as a response to special triggers-skin temperature change, rubbing, moisture, friction, etc.-while they do not penetrate into the skin and perform a local effect. MDSs can achieve a very high embedding capacity (50-60%), and as their pore size is very small (~0.25 цш), bacteria cannot penetrate inside, they do not need preservatives to obtain stability. They are usually administered in the form of a gel, and the aforementioned physical and physicochemical tests have to be accomplished with rheological studies (viscoelasticity) [141]. The disadvantage is that by the production only organic solvent technologies proved to be effective.

7.5.Microbubbles

Microbubbles are used as ultrasound contrasting agents, gene delivery vesicles, O2 carriers, are thrombolytic, and facilitate the transport through the blood-brain barrier without inducing a tissue-damaging effect [142]. Microbubble formulations contain an emulsifier, phospholipids, or protein components, which, following sonication, entrap gases (O2, perfluorocarbons, or sulfur hexafluoride). The product can be preserved in a lyophilized form. The maximum size may not exceed 10 цш to avoid embolism in vivo [143].

The in vivo performance of microbubbles is influenced by the complement system of the immune system, which is responsible for the removal of drug molecules, bacterial cells, and microbubbles from the circulation. Studies pointed out that PEGylation reduces the immunogenicity of BSA (bovine serum albumin) microbubbles [143].

8.Summary

In the past few decades, numerous microparticulate formulations gained therapeutical and diagnostical significance. A great number of polymers have been tested, of which several have been proved effective.

To accomplish the traditional coacervation, new methods have been developed (freeze-drying, spray drying, microfluidic flow-focusing, lithography, etc.). The various created structures offer a large potential for the fine-tuning of drug release mechanisms and the optimization of the pharmacokinetic profile.

Author Contributions: Formulation, characterization, polymer excipients, and use (M.L.); processes, release mechanisms (N.K.-S.); preparation, samples, and photos (V.A.); microfluidics (A.J.L.); and content, structure, and therapeutical aspects (I.A.).

Funding: This review article received no external funding.

Acknowledgments: The authors thank Ágnes Sárádi-Kesztyíis for technical assistance.

Conflicts of Interest: The authors declare no conflict of interest.

References

References

1. Bale, S.; Khurana, A.; Reddy, A.S.S.; Singh, M.; Godugu, C. Overview on Therapeutic Applications of Microparticle Drug Delivery Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems. Crit. Rev. Ther. Drug Carr. Syst. 2016, 4,309-361. [CrossRef] [PubMed]

2. Wang, B.H.; Longquin Hu, T.J.S. Drug Delivery to the Lymphatic System. In Drug Delivery Principles and Applications; Wang, B., Longquin Hu, T.J.S., Eds.; John Wiley and Sons Inc.: Hoboken, NJ, USA, 2016; p. 509. ISBN 9781118833230.

3. Whelehan, M.; Marison, I.W. Microencapsulation using vibrating technology. J. Microencapsul. 2011, 28, 669-688. [CrossRef] [PubMed]

4. Peanparkdee, M.; Iwamoto, S.; Yamauchi, R. Microencapsulation: A Review of Applications in the Food and Pharmaceutical Industries. Rev. Agric. Sci. 2016, 4, 56-65. [CrossRef]

5. Desai, T.; Shea, L.D. Advances in islet encapsulation technologies. Nat. Publ. Gr. 2016,16,338-350. [CrossRef] [PubMed]

6. Yi, Y.; Sanchez, L.; Gao, Y.; Yu, Y. Janus particles for biological imaging and sensing. Analyst 2016, 141, 3526-3539. [CrossRef] [PubMed]

7. Acter, S.; Cho, J.; Kim, J.W.; Byun, A.; Park, K.H.; Kim, J.W. Synthesis and shape control of uniform polymer microparticles by tailored adsorption of poly(ethylene oxide)-b-poly(?-caprolactone) copolymer. Bull. Korean Chem. Soc. 2015, 36,1467-1473. [CrossRef]

8. Gong, Z.; Hueckel, T.; Yi, G.R.; Sacanna, S. Patchy particles made by colloidal fusion. Nature 2017, 550, 234-238. [CrossRef]

9. Choi, K.; Salehizadeh, M.; Da Silva, R.B.; Hakimi, N.; Diller, E.; Hwang, D.K. 3D shape evolution of microparticles and 3D enabled applications using non-uniform UV flow lithography (NUFL). Soft Matter 2017,13, 7255-7263. [CrossRef]

10. Karami, N.; Moghimipour, E.; Salimi, A. Liposomes as a Novel Drug Delivery System: Fundamental and Pharmaceutical Application. Asian J. Pharm. 2018,12, S31-S41.

11. Rosenberg, R.T.; Dan, N.R. Diffusion through colloidosome shells. J. Colloid Interface Sci. 2011, 354,478-482. [CrossRef]

12. Yuan, Q.; Cayre, O.J.; Fujii, S.; Armes, S.P.; Williams, R.A.; Biggs, S. Responsive core-shell latex particles as colloidosome microcapsule membranes. Langmuir 2010, 26,18408-18414. [CrossRef] [PubMed]

13. Ozturk, A.G.; Ozturk, S.S.; Palsson, B.O.; Wheatley, T.A.; Dressman, J.B. Mechanism of release from pellets coated with an ethylcellulose-based film. J. Control. Release 1990,14, 203-213. [CrossRef]

14. Tang, E.S.K.; Chan, L.W.; Heng, P.W.S. Coating of multiparticulates for sustained release. Am. J. Drug Deliv. 2005, 3,17-28. [CrossRef]

15. Prajapati, V.D.; Jani, G.K.; Kapadia, J.R. Current knowledge on biodegradable microspheres in drug delivery. Expert Opin. Drug Deliv. 2015,12,1283-1299. [CrossRef] [PubMed]

16. Doty, A.C. Mechanistic Analysis of In Vivo and In Vitro Drug Release From PLGA Microspheres. Ph.D. Thesis, University of Michigan, Ann Arbor, ML, USA, 2015.

17. Bennet, D.; Kim, S.E.I. Application of Nanotechnology in Drug Delivery. In Polymer Nanoparticles for Smart Drug Delivery; Sezer, A.D., Ed.; InTechOpen: London, UK, 2014; ISBN 978-953-51-1628-8 b.

18. Senyei, A.; Widder, K.; Czerlinski, G. Magnetic guidance of drug-carrying microspheres. J. Appl. Phys. 1978, 49, 3578-3583. [CrossRef]

19. Farah, F.H. Magnetic Microspheres: A Novel Drug Delivery System. World, J. Pharm. Pharm. Sci. 2017, 3, 93-112. [CrossRef]

20. Foox, M.; Zilberman, M. Drug delivery from gelatin-based systems. Expert Opin. Drug Deliv. 2015, 12, 1547-1563. [CrossRef]

21. Rowe, R.C.; Sheskey, P.; Quinn, M. Handbook of Pharmaceutical Excipients, 7th ed.; Rowe, R.C., Sheskey, S.J., Cook, W.G.F.M., Eds.; Pharmaceutical Press: London, UK, 2009; ISBN 978-0857110275.

22. Inada, A.; Oue, T.; Yamashita, S.; Yamasaki, M.; Oshima, T.; Matsuyama, H. Development of highly water-dispersible complexes between coenzyme Q10 and protein hydrolysates. Eur. J. Pharm. Sci. 2019,136. [CrossRef]

23. Ju, Z.Y.; Kilara, A. Gelation of pH-Aggregated Whey Protein Isolate Solution Induced by Heat, Protease, Calcium Salt, and Acidulant. J. Agric. Food Chem. 1998, 8561,1830-1835. [CrossRef]

24. Peng, Z.G.; Hidajat, K.; Uddin, M.S. Adsorption of bovine serum albumin on nanosized magnetic particles. J. Colloid Interface Sci. 2004, 271, 277-283. [CrossRef]

25. Bouman, J. Controlled Release from Zein Matrices: Interplay of Drug Hydrophobicity and pH. Pharm. Res. 2016, 33, 673-685. [CrossRef] [PubMed]

26. Yong, Z.; Lili, C.; Feng, L.; Nianqiu, S.; Chunlei, L.; Xianghui, Y.; Yan, C.; Wei, K. Design, fabrication and biomedical applications of zein-based nano/micro-carrier systems. Int. J. Pharm. 2016, 512,191-210.

27. Lopes-da-Silva, J.A.; Monteiro, S.R. Gelling and emulsifying properties of soy protein hydrolysates in the presence of a neutral polysaccharide. Food Chem. 2019, 294,216-223. [CrossRef] [PubMed]

28. Shah, A.V.; Serajuddin, A.T.M.; Mangione, R.A. Making All Medications Gluten Free. J. Pharm. Sci. 2018, 107,1263-1268. [CrossRef] [PubMed]

29. Ranjha, N.M.; Khan, H. Encapsulation and characterization of controlled release flurbiprofen loaded microspheres using beeswax as an encapsulating agent. J. Mater. Sci. Mater. Med. 2010, 21, 1621-1630. [CrossRef] [PubMed]

30. Milanovic, J.; Manojlovic, V.; Levic, S.; Rajic, N.; Nedovic, V.; Bugarski, B. Microencapsulation of Flavors in Carnauba Wax. Sensors 2010,10, 901-912. [CrossRef]

31. Khor, C.M.; Ng, W.K.; Kanaujia, P.; Chan, K.P. Hot-melt extrusion microencapsulation of quercetin for taste-masking. J. Microencapsul. 2017, 34, 2048. [CrossRef]

32. Gopal, K.; Singh, K.; Halder, S.; Pati, S.; Wang, J. Microencapsulation of Paraffin Wax Microspheres with Silver. Def. Sci. J. 2018, 68, 218-224.

33. Rabani, F.; Aziz, A.; Jai, J.; Raslan, R.; Subuki, I. Microencapsulation of citronella oil by complex coacervation using chitosan-gelatin (b) system: Operating design, preparation and characterization. In MATEC Web of Conferences; EDP Sciences: Les Ulis, France, 2016.

34. Hussain, S.A.; Abdelkader, H.; Abdullah, N.; Kmaruddin, S. Review on micro-encapsulation with Chitosan for pharmaceuticals applications. MOJ Curr. Res. Rev. 2018,1, 77-84. [CrossRef]

35. Cunha, L.; Rodrigues, S.; Rosa, A.M.; Faleiro, L.; Buttini, F.; Grenha, A. Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment. Drug Dev. Ind. Pharm. 2019, 45,1313-1320. [CrossRef]

36. Lim, S.T.; Martin, G.P.; Berry, D.J.; Brown, M.B. Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. J. Control. Release 2000, 66, 281-292. [CrossRef]

37. Jia, X.; Yeo, Y.; Clifton, R.J.; Jiao, T.; Kohane, D.S.; Kobler, J.B.; Zeitels, S.M.; Langer, R. Hyaluronic Acid-Based Microgels and Microgel Networks for Vocal Fold Regeneration. Biomacromolecules 2006, 7, 3336-3344. [CrossRef] [PubMed]

38. Eraso, M.O.; Aníbal, H. Use of Starches and Milk Proteins in Microencapsulation. Int. J. Veg. Sci. 2014, 20, 289-304. [CrossRef]

39. Prabaharan, M. Prospective of guar gum and its derivatives as controlled drug delivery systems. Int. J. Biol. Macromol. 2011, 49,117-124. [CrossRef]

40. Kaity, S.; Isaac, J.; Ghosh, A. Interpenetrating polymer network of locust bean gum-poly (vinyl alcohol) for controlled release drug delivery. Carbohydr. Polym. 2013, 94, 456-467. [CrossRef] [PubMed]

41. Street, K.; Davé, V.; McCarthy, S. Review of konjac glucomannan. J. Polym. Environ. 1997, 5, 237-241.

42. Liu, J.; Xu, Q.; Zhang, J.; Zhou, X.; Lyu, F.; Zhao, P. Preparation, composition analysis and antioxidant activities of konjac. Carbohydr. Polym. 2015,130, 398-404. [CrossRef] [PubMed]

43. Necas, J.; Bartosikova, L. Carrageenan: A review. Vet. Med. 2013, 58,187-205. [CrossRef]

44. Sharratt, M.; Grasso, P.; Carpanini, F.; Gangolli, S.D. Carrageenan ulceration as a model for human ulcerative colitis. Lancet 1971, 297,192-193. [CrossRef]

45. Mano, F.; Reis, R.L.; Gasperini, L. Natural polymers for the microencapsulation of cells. J. R. Soc. Interface 2014, 11, 20140817.

46. Kim, D.Y.; Kwon, D.Y.; Kwon, J.S.; Kim, J.H.; Min, B.H.; Kim, M.S. Stimuli-responsive injectable in situ-forming hydrogels for regenerative medicines. Polym. Rev. 2015, 55, 407-452. [CrossRef]

47. Asghari-varzaneh, E.; Shahedi, M.; Shekarchizadeh, H. Iron microencapsulation in gum tragacanth using solvent evaporation method. Int. J. Biol. Macromol. 2017,103, 640-647. [CrossRef] [PubMed]

48. Edris, A.E.; Kalemba, D.; Adamiec, J.; Piaotkowski, M. Microencapsulation of Nigella sativa oleoresin by spray drying for food and nutraceutical applications. Food Chem. 2016, 204, 326-333. [CrossRef] [PubMed]

49. Williams, P.A.; Phillips, G.O. Handbook of Hydrocolloids; CRC Press: Boca Raton, FL, USA, 2009; ISBN 9781845694142.

50. Sammour, A. Optimization of the MIcroencapsulation of Lavender Oil by Spray Drying. J. Microencapsul. 2019,17,1-42.

51. Endress, H. Nonfood Uses of Pectin; Academic Press, Inc.: Cambridge, MA, USA, 1991.

52. Wong, T.W.; Colombo, G.; Sonvico, F. Pectin Matrix as Oral Drug Delivery Vehicle for Colon Cancer Treatment. AAPS PharmSciTech 2011,12, 201-214. [CrossRef]

53. Petri, D.F.S. Xanthan gum: A versatile biopolymer for biomedical and technological applications. J. Appl. Polym. Sci. 2015, 132. [CrossRef]

54. Mahdi, M.H.; Conway, B.R.; Smith, A.M. Development of mucoadhesive sprayable gellan gum fluid gels. Int. J. Pharm. 2015, 488,12-19. [CrossRef]

55. Varshosaz, J.; Ahmadi, F.; Emami, J.; Tavakoli, N.; Minaiyan, M.; Mahzouni, P.; Dorkoosh, F. Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: An in vitro/in vivo evaluation in induced colitis in rat. J. Microencapsul. 2011, 28, 62-73. [CrossRef]

56. Kadota, K.; Yanagawa, Y.; Tachikawa, T.; Deki, Y.; Uchiyama, H.; Shirakawa, Y.; Tozuka, Y. Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-Department of Chemical Engineering and Material Science, Doshisha University, 1-3. Int. J. Pharm. 2018. [CrossRef]

57. Kshirsagar, A.C.; Yenge, V.B.; Sarkar, A.; Singhal, R.S. Efficacy of pullulan in emulsification of turmeric oleoresin and its subsequent microencapsulation. Food Chem. 2009,113,1139-1145. [CrossRef]

58. Prajapati, V.D.; Jani, G.K.; Khanda, S.M. Pullulan: An exopolysaccharide and its various applications. Carbohydr. Polym. 2013, 95, 540-549. [CrossRef] [PubMed]

59. Chowdary, K.P.R.; Rao, Y.S. Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: A technical note. AAPS PharmSciTech 2004, 4, 87-92. [CrossRef] [PubMed]

60. Cardenas-Bailon, F.; Osorio-Revilla, G.; Gallardo-Velazquez, T. Microencapsulation of insulin using a W/O/W double emulsion followed by complex coacervation to provide protection in the gastrointestinal tract. J. Microencapsul. 2015, 32, 308-316. [CrossRef] [PubMed]

61. Mansuri, S.; Kesharwani, P.; Jain, K.; Tekade, R.K.; Jain, N.K. Mucoadhesion: A promising approach in drug delivery system. React. Funct. Polym. 2016,100,151-172. [CrossRef]

62. Karewicz, A.; Zasada, K.; Bielska, D.; Douglas, T.E.L.; Jansen, J.A.; Leeuwenburgh, S.C.G.; Nowakowska, M. Alginate-hydroxypropylcellulose hydrogel microbeads for alkaline phosphatase encapsulation. J. Microencapsul. 2014, 2048, 68-76. [CrossRef] [PubMed]

63. Katona, J.M.; Sovilj, V.J.; Petrovic, L.B. Microencapsulation of oil by polymer mixture-ionic surfactant interaction induced coacervation. Carbohydr. Polym. 2010, 79, 563-570. [CrossRef]

64. Jelvehgari, M.; Siahi-Shadbad, M.R.; Azarmi, S.; Martin, G.P.; Nokhodchi, A. The microsponge delivery system of benzoyl peroxide: Preparation, characterization and release studies. Int. J. Pharm. 2006, 308, 124-132. [CrossRef] [PubMed]

65. Fundueanu, G.; Constantin, M.; Esposito, E.; Cortesi, R.; Nastruzzi, C.; Menegatti, E. Cellulose acetate butyrate microcapsules containing dextran ion-exchange resins as self-propelled drug release system. Biomaterials 2005, 26, 4337-4347. [CrossRef] [PubMed]

66. Koga, C.C.; Lee, S.; Lee, Y. Consumer Acceptance of Bars and Gummies with Unencapsulated and Encapsulated Resveratrol. J. Food Sci. 2016, 81,1222-1229. [CrossRef] [PubMed]

67. Kapoor, D.N.; Bhatia, A.; Kaur, R.; Sharma, R.; Kaur, G.; Dhawan, S. PLGA: A unique polymer for drug delivery. Ther. Deliv. 2015, 6, 41-58. [CrossRef] [PubMed]

68. Bilati, U.; Allémann, E.; Doelker, E. Poly(D,L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method-Processing and formulation issues for enhanced entrapment efficiency. J. Microencapsul. 2005,22, 205-214. [CrossRef] [PubMed]

69. Qu, S.; Dai, C.; Yang, F.; Huang, T.; Hao, Z.; Tang, Q.; Wang, H. Cefquinome-Loaded Microsphere Formulations in Protection against Pneumonia with Klebsiella pneumonia Infection and Inflammatory Response in Rats. Pharm. Res. 2019, 36, 74. [CrossRef] [PubMed]

70. Tian, Y.; Grishkewich, N.; Bromberg, L.; Hatton, T.A.; Tam, K.C. Cross-linked Pluronic-g-Polyacrylic acid Microgel system for the Controlled Release of Doxorubicin in Pharmaceutical Formulations. Eur. J. Pharm. Biopharm. 2017,114, 230-238. [CrossRef] [PubMed]

71. Al-kasmi, B.; Alsirawan, M.H.D.B.; Bashimam, M.; El-zein, H. Mechanical microencapsulation: The best technique in taste masking for the manufacturing scale-Effect of polymer encapsulation on drug targeting. J. Control. Release 2017,260,134-141. [CrossRef] [PubMed]

72. Wang, W.; Liu, L.; Ju, X.; Zerrouki, D.; Xie, R.; Yang, L.; Chu, L. A Novel Thermo-Induced Self-Bursting Microcapsule with Magnetic-Targeting Property. Chem. Phys. Chem. 2009, 10, 2405-2409. [CrossRef] [PubMed]

73. Li, X. Synthesis and properties of thermo-responsive guar gum/poly (N-isopropylacrylamide) interpenetrating polymer network hydrogels. Carbohydr. Polym. 2008, 71, 394-402. [CrossRef]

74. Wattendorf, U.T.A.; Merkle, H.P. PEGylation as a Tool for the Biomedical Engineering of Surface Modified Microparticles. J. Pharm. Sci. 2008, 97, 4655-4669. [CrossRef]

75. Heinemann, L.; Baughman, R.; Boss, A.; Hompesch, M. Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin. J. Diabetes Sci. Technol. 2017,11,148-156. [CrossRef]

76. Sæ ther, H.V.; Holme, H.K.; Maurstad, G.; Smidsrød, O.; Stokke, B.T. Polyelectrolyte complex formation using alginate and chitosan. Carbohydr. Polym. 2008, 74,813-821. [CrossRef]

77. Batubara, I.; Rahayu, D.; Mohamad, K.; Prasetyaningtyas, W.E. Leydig Cells Encapsulation with Alginate-Chitosan: Optimization of Microcapsule Formation. J. Encapsulation Adsorpt. Sci. 2012, 2, 15-20. [CrossRef]

78. Capretto, L.; Mazzitelli, S.; Luca, G.; Nastruzzi, C. Preparation and characterization of polysaccharidic microbeads by a microfluidic technique: Application to the encapsulation of Sertoli cells. Acta Biomater. 2010, 6, 429-435. [CrossRef] [PubMed]

79. Santos, M.G.; Bozza, F.T.; Thomazini, M.; Favaro-Trindade, C.S. Microencapsulation of xylitol by double emulsion followed by complex coacervation. Food Chem. 2015,17!, 32-39. [CrossRef] [PubMed]

80. Shaddel, R.; Hesari, J.; Azadmard-damirchi, S.; Hamishehkar, H. Use of gelatin and gum Arabic for encapsulation of black raspberry anthocyanins by complex coacervation. Int. J. Biol. Macromol. 2017,107, 1800-1810. [CrossRef] [PubMed]

81. Bhattacharya, S.S.; Shukla, S.; Banerjee, S.; Chowdhury, P.; Chakraborty, P.; Ghosh, A. Tailored IPN Hydrogel Bead of Sodium Carboxymethyl Cellulose and Sodium Carboxymethyl Xanthan Gum for Controlled Delivery of Diclofenac Sodium. Polym. Plast. Technol. Eng. 2013, 52, 795-805. [CrossRef]

82. Maciel, V.B.V.; Yoshida, C.M.P.; Pereira, S.M.S.S.; Goycoolea, F.M.; Franco, T.T. Nano- and Microparticles for Insulin Delivery. Molecules 2017,22,1707. [CrossRef]

83. Rocha-Selmi, G.A.; Theodoro, A.C.; Thomazini, M.; Bolini, H.M.A.; Favaro-Trindade, C.S. Double emulsion stage prior to complex coacervation process for microencapsulation of sweetener sucralose. J. Food Eng. 2013, 119,28-32. [CrossRef]

84. Carneiro, H.C.F.; Tonon, R.V.; Grosso, C.R.F.; Hubinger, M.D. Encapsulation efficiency and oxidative stability of flaxseed oil microencapsulated by spray drying using different combinations of wall materials. J. Food Eng. 2013,115,443-451. [CrossRef]

85. Fioramonti, S.A.; Stepanic, E.M.; Tibaldo, A.M.; Pavón, Y.L.; Santiago, L.G. Spray dried flaxseed oil powdered microcapsules obtained using milk whey proteins-alginate double layer emulsions. Food Res. Int. 2019,119, 931-940. [CrossRef]

86. Alvarado, Y.; Muro, C.; Illescas, J.; Díaz, M.D.C.; Riera, F. Encapsulation of Antihypertensive Peptides from Whey Proteins and Their Releasing in Gastrointestinal Conditions. Biomolecules 2019, 9,164. [CrossRef]

87. Riaz, T.; Iqbal, M.W.; Saeed, M.; Yasmin, I.; Hassanin, H.A.; Mahmood, S.; Rehman, A. In-vitro survival of Bifidobacterium bifidum microencapsulated in zein coated alginate hydrogel microbeads. J. Microencapsul. 2019, 36,192-203. [CrossRef]

88. Farris, E.; Brown, D.M.; Ramer-Tait, A.E.; Pannier, A.K. Chitosan-zein nano-in-microparticles capable of mediating in vivo transgene expression following oral delivery. J. Control. Release 2017, 249, 150-161. [CrossRef] [PubMed]

89. Gardner, C.M.; Burke, N.A.D.; Stöver, H.D.H. Cross-linked microcapsules formed from self-deactivating reactive polyelectrolytes. Langmuir 2010, 26, 4916-4924. [CrossRef] [PubMed]

90. Giovagnoli, S.; Blasi, P.; Luca, G.; Fallarino, F.; Calvitti, M.; Mancuso, F.; Ricci, M.; Basta, G.; Becchetti, E.; Rossi, C.; et al. Bioactive long-term release from biodegradable microspheres preserves implanted ALG-PLO-ALG microcapsules from in vivo response to purified alginate. Pharm. Res. 2010, 27, 285-295. [CrossRef] [PubMed]

91. Mooranian, A.; Negrulj, R.; Al-Salami, H.; Morahan, G.; Jamieson, E. Designing anti-diabetic ß-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis. Biotechnol. Prog. 2016, 32, 501-509. [CrossRef] [PubMed]

92. Wells, L.A.; Sheardown, H. Photosensitive controlled release with polyethylene glycol-anthracene modified alginate. Eur. J. Pharm. Biopharm. 2011, 79, 304-313. [CrossRef] [PubMed]

93. Mahou, R.; Meier, R.R.H.; Bühler, L.H.; Wandrey, C. Alginate-poly(ethylene glycol) hybrid microspheres for primary cell microencapsulation. Materials 2014, 7, 275-286. [CrossRef]

94. Colinet, I.; Dulong, V.; Mocanu, G.; Picton, L.; Le Cerf, D. New amphiphilic and pH-sensitive hydrogel for controlled release of a model poorly water-soluble drug. Eur. J. Pharm. Biopharm. 2009, 73, 345-350. [CrossRef]

95. Streubel, A.; Siepmann, J.; Bodmeier, R. Floating microparticles based on low density foam powder. Int. J. Pharm. 2002, 241, 279-292. [CrossRef]

96. Wu, J.; Kong, T.; Yeung, K.W.K.; Shum, H.C.; Cheung, K.M.C.; Wang, L.; To, M.K.T. Fabrication and characterization of monodisperse PLGA-alginate core-shell microspheres with monodisperse size and homogeneous shells for controlled drug release. Acta Biomater. 2013, 9, 7410-7419. [CrossRef]

97. Funami, T.; Kataoka, Y.; Omoto, T.; Goto, Y. Food hydrocolloids control the gelatinization and retrogradation behavior of starch. 2a. Functions of guar gums with different molecular weights on the gelatinization behavior of corn starch q. Food Hydrocoll. 2005,19,15-24. [CrossRef]

98. Papa, S.; Veglianese, P. Improving the Pharmacodynamic and Pharmacological Profile of Bioactive Molecules Using Biopolymers; Elsevier Ltd.: Amsterdam, The Netherlands, 2016; ISBN 9780081002667.

99. Dalpiaz, A.; Fogagnolo, M.; Ferraro, L.; Capuzzo, A.; Pavan, B.; Rassu, G.; Salis, A.; Giunchedi, P.; Gavini, E. Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antiviral Res. 2015,123, 146-157. [CrossRef] [PubMed]

100. Haque, T.P.S. Superior Cell Delivery Features of Poly(ethylene glycol) Incorporated Alginate, Chitosan, and Poly-L-lysine Microcapsules. Mol. Pharm. 2004, 2, 29-36. [CrossRef] [PubMed]

101. McNaught, A.W.A. International Union of Pure and Applied Chemistry Compendium of Chemical Terminology Gold Book; Version 2; Pergamon Press: Oxford, UK, 1978.

102. Chuang, J.J.; Huang, Y.Y.; Lo, S.H.; Hsu, T.F.; Huang, W.Y.; Huang, S.L.; Lin, Y.S. Effects of pH on the Shape of Alginate Particles and Its Release Behavior. Int. J. Polym. Sci. 2017, 2017, 9. [CrossRef]

103. Nemethova, V.; Lacik, I.; Razga, F. Vibration Technology for Microencapsulation: The Restrictive Role of Viscosity. J. Bioprocess. Biotech. 2015, 5. [CrossRef]

104. Wurster, D.E.; Bhattacharjya, S.; Flanagan, D.R. Effect of Curing on Water Diffusivities in Acrylate Free Films as Measured via a Sorption Technique. AAPS PharmSciTech 2007, 8,1-6. [CrossRef] [PubMed]

105. Das, S.K.; David, S.R.; Rajabalaya, R.; Halder, T. Microencapsulation techniques and its practices. Int. J. Pharm. Sci. Tech. 2011, 6,1.

106. Poncelet, D. Microencapsulation: Fundamentals, methods and applications. In Surface Chemistry in Biomed Environmental Science; Springer: Dordrecht, The Netherlands, 2006; pp. 26-34. ISBN 140204741X.

107. Klokk, T.I.; Melvik, J.E. Controlling the size of alginate gel beads by use of a high electrostatic potential. J. Microencapsul. 2002,19,415-424. [CrossRef]

108. Watanabe, A.; Hanawa, T.; Sugihara, M.; Yamamoto, K. Development and pharmaceutical properties of a new oral dosage form of theophylline using sodium caseinate for the possible use in elderly patients. Int. J. Pharm. 1995,117, 23-30. [CrossRef]

109. Manojlovic, V.; Djonlagic, J.; Obradovic, B.; Nedovic, V.; Bugarski, B. Immobilization of cells by electrostatic droplet generation: A model system for potential application in medicine. Int. J. Nanomed. 2006,1,163-171. [CrossRef]

110. Haeberle, S.; Naegele, L.; Burger, R.; Zengerle, R.; Ducrée, J. Alginate Micro-Bead Fabrication on a Centrifugal Microfluidics Platform. In Proceedings of the 2007 IEEE 20th International Conference on Micro Electro Mechanical Systems (MEMS), Hyogo, Japan, 21-25 January 2007. [CrossRef]

111. Ezhilarasi, P.N.; Karthik, P.; Chhanwal, N.; Anandharamakrishnan, C. Nanoencapsulation Techniques for Food Bioactive Components: A Review. Food Bioprocess Technol. 2013, 6, 628-647. [CrossRef]

112. Emami, F.; Vatanara, A.; Park, E.J.; Na, D.H. Drying technologies for the stability and bioavailability of biopharmaceuticals. Pharmaceutics 2018,10,131. [CrossRef] [PubMed]

113. Dittrich, P.S.; Manz, A. Lab-on-a-chip: Microfluidics in drug discovery. Nat. Rev. Drug Discov. 2006, 5, 210-218. [CrossRef] [PubMed]

114. Damiati, S. Microfluidic Devices for Drug Delivery Systems and Drug Screening. Genes 2018, 9, 103. [CrossRef] [PubMed]

115. Zhu, P.; Wang, L. Lab on a Chip Passive and active droplet generation with microfluidics: A review. Lab Chip 2017,17, 34-75. [CrossRef] [PubMed]

116. Nisisako, T. Recent advances in microfluidic production of Janus droplets and particles. Curr. Opin. Colloid Interface Sci. 2016,25,1-12. [CrossRef]

117. Fang, Y.; Li, L.; Vreeker, R.; Yao, X.; Wang, J.; Ma, Q.; Jiang, F.; Phillips, G.O. Rehydration of dried alginate gel beads: Effect of the presence of gelatin and gum arabic. Carbohydr. Polym. 2011, 86,1145-1150. [CrossRef]

118. Hakimi, N.; Tsai, S.S.H.; Cheng, C.H.; Hwang, D.K. One-step two-dimensional microfluidics-based synthesis of three-dimensional particles. Adv. Mater. 2014, 26, 1393-1398. [CrossRef]

119. Le Goff, G.C.; Lee, J.; Gupta, A.; Hill, W.A.; Doyle, P.S. High-Throughput Contact Flow Lithography. Adv. Sci. 2015, 2,1500149. [CrossRef]

120. Shekunov, B.Y.; Chattopadhyay, P.; Tong, H.H.Y.; Chow, A.H.L. Particle size analysis in pharmaceutics: Principles, methods and applications. Pharm. Res. 2007,24, 203-227. [CrossRef]

121. Shahi, S.; Pharmaceuticals, L. Micro particles: An approach for betterment of drug delivery system. Int. J. Pharm. Res. Dev. 2014,1,99-115.

122. Hasirci, V.; Hasirci, N. Fundamentals of Biomaterials; Springer: Berlin/Heidelberg, Germany, 2018; ISBN 9788847011946.

123. Chou, D.K.; Krishnamurthy, R.; Randolph, T.W.; Carpenter, J.F.; Manning, M.C. Effects of Tween 20®and Tween 80®on the stability of Albutropin during agitation. J. Pharm. Sci. 2005, 94,1368-1381. [CrossRef] [PubMed]

124. Patel, M.A.; AbouGhaly, M.H.H.; Schryer-Praga, J.V.; Chadwick, K. The effect of ionotropic gelation residence time on alginate cross-linking and properties. Carbohydr. Polym. 2017,155,362-371. [CrossRef]

125. Song, M.; Li, N.; Tiedt, L.R.; Degennaro, M.D.; de Villiers, M.M. Preparation and Characterization of Highly Porous Direct Compression Carrier Particles with Improved Drug Loading During an Interactive Mixing Process. AAPS PharmSciTech 2010,11, 698-707. [CrossRef] [PubMed]

126. Lengyel, M.; Balogh, E.; Szeroczei, D.; Dobó-Nagy, C.; Pápay, Z.; Stömmer, V.; Klebovich, I.; Antal, I. Study on process parameters and optimization of microencapsulation based on phase separation. Eur. J. Pharm. Sci. 2018,122, 273-280. [CrossRef] [PubMed]

127. Dong, W.Y.; Maincent, P.; Bodmeier, R. In vitro and in vivo evaluation of carbamazepine-loaded enteric microparticles. Int. J. Pharm. 2007, 331, 84-92. [CrossRef] [PubMed]

128. Adebisi, A.O.; Conway, B.R. Preparation and characterisation of gastroretentive alginate beads for targeting H. pylori. J. Microencapsul. 2014, 31, 58-67. [CrossRef] [PubMed]

129. El-Say, K.M. Maximizing the encapsulation efficiency and the bioavailability of controlled-release cetirizine microspheres using Draper-Lin small composite design. Drug Des. Dev. Ther. 2016,10, 825-839. [CrossRef]

130. Dredán, J.; Antal, I.; Rácz, I. Evaluation of mathematical models describing drug release from lipophilic matrices. Int. J. Pharm. 1996,145, 61-64. [CrossRef]

131. Tigli Aydin, R.S.; Pulat, M. 5-fluorouracil encapsulated chitosan nanoparticles for pH-stimulated drug delivery: Evaluation of controlled release kinetics. J. Nanomater. 2012, 2012, 42. [CrossRef]

132. Son, Y.J.; McConville, J.T. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int. J. Pharm. 2009, 382,15-22. [CrossRef]

133. Rawat, A.; Bhardwaj, U.; Burgess, D.J. Comparison of in vitro-in vivo release of Risperdal® Consta® microspheres. Int. J. Pharm. 2012, 434,115-121. [CrossRef] [PubMed]

134. Salama, R.O.; Traini, D.; Chan, H.; Young, P.M. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur. J. Pharm. Biopharm. 2008, 70,145-152. [CrossRef] [PubMed]

135. Arora, D.; Shah, K.A.; Halquist, M.S.; Sakagami, M. In Vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products. Pharm. Res. 2010, 27, 786-795. [CrossRef] [PubMed]

136. Gerde, P.; Malmlöf, M.; Havsborn, L.; Sjöberg, C.-O.; Ewing, P.; Eirefelt, S.; Ekelund, K. Dissolv It: An In Vitro Method for Simulating the Dissolution and Absorption of Inhaled Dry Powder Drugs in the Lungs. Assay Drug Dev. Technol. 2017,15, 77-88. [CrossRef] [PubMed]

137. Zhou, J.; Suo, Z. Strengthening Alginate/Polyacrylamide Hydrogels Using Various Multivalent Cations. ACS Appl. Mater. Interfaces 2013, 5,10418-10422.

138. Sgouras, D.; Duncan, R. Methods for the evaluation of biocompatibility of soluble synthetic polymers which have potential for biomedical use: 1-Use of the tetrazolium-based colorimetric assay (MTT) as a preliminary screen for evaluation of in vitro cytotoxicity. J. Mater. Sci. Mater. Med. 1990,1, 61-68. [CrossRef]

139. Leone-Bay, A.; Baughman, R.; Smutney, C.; Kocinsky, J. Innovations in Drug Delivery by Inhalation. OnDrugDelivery Magazine. November 2010, pp. 4-8. Available online: https://www.ondrugdelivery.com/wpcontent/uploads/2018/11/Nov2010.pdf (accessed on 27 June 2019).

140. Murry, D.J.; Blaney, S.M. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann. Pharmacother. 2000, 34,1173-1178. [CrossRef]

141. Singhvi, G.; Manchanda, P.; Hans, N.; Dubey, S.K.; Gupta, G. Microsponge: An emerging drug delivery strategy. Drug Dev. Res. 2019, 80, 200-208. [CrossRef]

142. Marquet, F.; Teichert, T.; Wu, S.Y.; Tung, Y.S.; Downs, M.; Wang, S.; Chen, C.; Ferrera, V.; Konofagou, E.E. Real-time, transcranial monitoring of safe blood-brain barrier opening in non-human primates. PLoS ONE 2014, 9,1-11. [CrossRef]

143. Upadhyay, A.; Dalvi, S.V.; Gupta, G.; Khanna, N. Effect of PEGylation on performance of protein microbubbles and its comparison with lipid microbubbles. Mater. Sci. Eng. C 2017, 71,425-430. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).